by Fred Dumais | Mar 22, 2024 | News Release
MONTREAL, QUEBEC, March 22, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company’s Board of Directors. “We are very pleased...
by Fred Dumais | Mar 14, 2024 | Communiqué de presse
Revenus de 13,5 millions $ en T1-24, en hausse de 3 % comparativement à T1-23 Perte de BAIIA ajusté de 2,1 millions $ en T1-24, contre 2,2 millions $ en T1-23, soit une baisse de 6 % Le nombre total de prescriptions pour Enerzair et Atectura pour les 12 mois se...
by Fred Dumais | Mar 14, 2024 | News Release
Q1-24 revenues of $13.5 million, up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for the 12 months ending January 31, 2024, exceeded 78,000, up 130% over the 12...
by Fred Dumais | Mar 7, 2024 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 7 mars 2024 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers et...
by Fred Dumais | Mar 7, 2024 | News Release
MONTREAL, QUEBEC , March 7, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2024...
